116
Participants
Start Date
July 29, 2024
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2027
IBI3003
Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
SUSPENDED
Wollongong Private Hospital, Wollongong
SUSPENDED
St Vincent's Hospital, Melbourne
SUSPENDED
Austin Hospital, Heidelberg
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
ZhongShan Hospital FuDan University, Shanghai
NOT_YET_RECRUITING
Jiangsu Province Hospital, Nanjing
NOT_YET_RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
NOT_YET_RECRUITING
Tianjin Medical University General Hospital, Tianjin
NOT_YET_RECRUITING
Jiangxi Cancer Hospital, Nanchang
RECRUITING
Tongji Medical College of HUST Tongji Hospital, Wuhan
NOT_YET_RECRUITING
The first Affiliated Hospital of Guangxi Medical University, Nanning
NOT_YET_RECRUITING
The First Affiliated Hospital of XI'AN Jiaotong University, Xian
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY